For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Sumitomo Braced for Red Ink to Continue in FY2023 on Latuda LOE
November 1, 2022
- Sumitomo Posts 7.3 Billion Yen Net Loss in H1 on Kynmobi Write-Down
November 1, 2022
- Ono’s April-September Sales Zoom 24.5% on Bullish Opdivo and Forxiga
November 1, 2022
- Takeda, Shionogi to Wind Up Copromotion for 2 ADHD Products
November 1, 2022
- Average Price Gap for 2023 Revision Looks to Be a Bit Lower than 7.6%: Wholesalers
November 1, 2022
- Novartis Challenges US Court Verdict on Tafinlar Patent Infringement
October 31, 2022
- Kyowa Kirin Files Hyperphosphatemia Drug in Japan
October 31, 2022
- Hisamitsu’s Osteoarthritis Patch Drug Fails in US PIII Study
October 31, 2022
- Opdivo Snags South Korea Nod for Neoadjuvant Use in NSCLC
October 31, 2022
- Takeda’s H1 Sales Up 10% Backed by Robust Mainstays, Hefty FX Gains
October 28, 2022
- Cancer-Savvy New CMO Eager to Extend Astellas’ Oncology Portfolio, Bag Speedy Approval
October 28, 2022
- Takeda Files SC Immunoglobulin for Immune Disorders in Japan
October 27, 2022
- Sanofi Seeks Dupixent’s Pediatric Dosage for Eczema in Japan
October 27, 2022
- Astellas Bags Option Rights to 2 Taysha Gene Therapy Programs
October 26, 2022
- Toho Picked as Single Wholesaler for LEO Pharma’s Dovonex
October 26, 2022
- Daiichi Sankyo’s FLT3 Inhibitor Gets FDA’s Priority Review for 1st Line AML
October 26, 2022
- Chugai Logs Bumper Earnings in January-September on New Products, Exports to Roche
October 25, 2022
- Bayer Launches Xarelto Tablets 2.5 mg for PAD as Single-Channel Product
October 25, 2022
- LEO Pharma to Take Over Dovonex Distribution, Set Up Solo Sales Regime in Japan
October 25, 2022
- GSK Seeks Japan Approval of RSV Vaccine
October 24, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…